Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022.
Similarly What is the target price for BCRX stock? Stock Price Targets
| High | $30.00 |
|---|---|
| Median | $17.50 |
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
il y a 4 jours
Why is AUPH stock going down? Why Aurinia Pharmaceuticals Tumbled Despite Its ‘Aggressive’ 2022 Outlook. Aurinia topped fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for lupus treatment Lupkynis.
Additionally, Will BCRX go up?
The 12 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a +53.64% increase from the last price of 11.39.
Is Bcrx a buy right now?
BioCryst Pharmaceuticals has received a consensus rating of Buy.
Will BXRX stock go up? Stock Price Forecast
The 2 analysts offering 12-month price forecasts for Baudax Bio Inc have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +307.61% increase from the last price of 1.84.
Why is OCGN stock down? Ocugen’s OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.
Is BioCryst a good stock to buy? Is BioCryst Pharmaceuticals stock A Buy? The BioCryst Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe BioCryst Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Why is BioCryst going up?
The big gain came after the company provided an upbeat update on Monday. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million.
When did BCRX go public? When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
Is BioCryst a good investment?
Is BioCryst Pharmaceuticals stock A Buy? Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for BioCryst Pharmaceuticals stock to perform well in the short-term.
Is BCRX overvalued? Slightly overvalued with limited growth.
Is BioCryst Pharmaceuticals a good stock to buy?
Zacks’ proprietary data indicates that BioCryst Pharmaceuticals, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the BCRX shares relative to the market in the next few months.
Is BXRX a good investment?
Out of 2 analysts, 2 (100%) are recommending BXRX as a Strong Buy, 0 (0%) are recommending BXRX as a Buy, 0 (0%) are recommending BXRX as a Hold, 0 (0%) are recommending BXRX as a Sell, and 0 (0%) are recommending BXRX as a Strong Sell. What is BXRX’s earnings growth forecast for 2022-2024?
Is BXRX a good buy? (BXRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company’s earnings prospects.
Is BXRX a good stock to buy? (BXRX), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates — one of the most powerful forces impacting stock prices. A company’s changing earnings picture is at the core of the Zacks rating.
Will OCGN go up?
Long-term Ocugen stock forecast 2022-2025
Algorithm-based forecasting service Wallet Investor gave a positive OCGN stock price forecast. The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
Is OCGN stock a buy? During the day the stock fluctuated 9.03% from a day low at $2.77 to a day high of $3.02. The price has fallen in 8 of the last 10 days and is down by -11.87% for this period.
…
Predicted Opening Price for Ocugen Inc of Thursday, April 14, 2022.
| Fair opening price April 14, 2022 | Current price |
|---|---|
| $2.92 | $2.97 (Overvalued) |
Is OCGN a buy or sell?
Ocugen has received a consensus rating of Hold. The company’s average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Is Bcrx overvalued? Slightly overvalued with limited growth.
What does BioCryst Pharmaceuticals do?
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. We are passionate about advancing novel therapeutics for patients with rare and serious diseases.